PMID- 16702804
OWN - NLM
STAT- MEDLINE
DCOM- 20070116
LR  - 20211203
IS  - 0959-4973 (Print)
IS  - 0959-4973 (Linking)
VI  - 17
IP  - 5
DP  - 2006 Jun
TI  - Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase 
      pathway.
PG  - 487-94
AB  - The mammalian target of rapamycin (mTOR) is a threonine kinase involved in 
      intracellular pro-survival signaling. Its activation leads to progression from 
      the G1 to S phase of the cell cycle. Constitutive activation of the mTOR-related 
      messengers, including phosphatidylinositol 3-kinase, Akt kinase, ribosomal p70S6 
      kinase and eukaryotic translation initiation factor 4E-binding protein kinase, 
      was found in numerous malignancies. Recent data indicate that the mTOR kinase 
      pathway can be an attractive target for anti-cancer drug development. A 
      well-known mTOR inhibitor is rapamycin (RAPA), previously applied as an 
      immunosuppressive agent in transplant studies. Recently, analogs of RAPA, such as 
      CCI-779, RAD001 and AP23573, have been developed. All of those agents are 
      currently being tested in patients with solid or hematological tumors in several 
      clinical trials. This review presents recent developments in targeting the mTOR 
      kinase pathway.
FAU - Smolewski, Piotr
AU  - Smolewski P
AD  - Department of Hematology, Medical University of Lodz, Lodz, Poland. 
      piotr_smolewski@wp.pl
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 48Z35KB15K (ridaforolimus)
RN  - 624KN6GM2T (temsirolimus)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - *Antineoplastic Agents/chemistry/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Design
MH  - Enzyme Activation/drug effects
MH  - Everolimus
MH  - Humans
MH  - Neoplasms/*drug therapy/enzymology
MH  - *Protein Kinase Inhibitors/chemistry/pharmacology/therapeutic use
MH  - *Protein Kinases/drug effects/physiology
MH  - *Signal Transduction/drug effects
MH  - Sirolimus/analogs & derivatives/chemistry/pharmacology
MH  - TOR Serine-Threonine Kinases
RF  - 77
EDAT- 2006/05/17 09:00
MHDA- 2007/01/17 09:00
CRDT- 2006/05/17 09:00
PHST- 2006/05/17 09:00 [pubmed]
PHST- 2007/01/17 09:00 [medline]
PHST- 2006/05/17 09:00 [entrez]
AID - 00001813-200606000-00001 [pii]
AID - 10.1097/00001813-200606000-00001 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2006 Jun;17(5):487-94. doi: 10.1097/00001813-200606000-00001.